Mikhail “misha” Plam

Biography

Dr. Plam is cofounder of AmideBio, LLC. Prior to AmideBio Dr. Plam was Founder, President and CEO of BiOptix, commercial provider of a novel Surface Plasmon Resonance-enhanced Common Path Interferometer system platform used for the detection of molecular interactions. In 1994 Dr. Plam founded and served as Chairman, President and CEO of Sievers Instruments, an analytical instrument company acquired by General Electric (NYSE: GE). In 1997, Dr. Plam was selected as the Ernst & Young Entrepreneur-of-the-Year (Rocky Mountain Region), was named Entrepreneur of Distinction at Esprit ’97 Boulder (Colorado) and in 2010 he received University of Colorado Serial Startup Entrepreneur Award. In 2011, Dr. Plam received SBA/Tibbets award for propagation of SBIR program in several countries and successful commercialization of technologies. Dr. Plam is a member the Advisory Board at The University of Colorado Center for Entrepreneurship. 

Research Interest

AmideBio is a preclinical stage biotech company pursuing a series of therapeutic targets and diagnostic in the diabetes space. These include ultrastable insulin, glucose sensing insulin, solution stable glucagon and improved diagnostics for juvenile (T1) diabetes. In the diabetes space, a library of single chain insulin (SCI) analogs have been manufactured using a proprietary design protocol optimized for the production of SCI analogs that are resistant to thermal and chemical degradation at elevated temperature while maintaining maximal bioactivity